Brief: Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01
07/10/2025 12:52
Oct 7 (Reuters) - Relmada Therapeutics Inc RLMD.O: RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01 Source text: ID:nGNX8jQgpY Further company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million